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Objective: Endovascular repair of thoracic aortic disease is rapidly progressing as an alternative to open surgical
therapy. In March of 2005, the Gore TAG thoracic endoprosthesis (W. L. Gore & Associates, Inc, Flagstaff, Ariz)
received Food and Drug Administration (FDA) approval for the treatment of descending thoracic aortic aneu-
rysms. Subsequently, off-label use of the technology expanded to include additional thoracic aortic diseases.
The purpose of this study was to examine whether the outcomes with this device changed after the inclusion
and exclusion criteria of FDA-controlled trials no longer governed patient selection.
Methods: A retrospective analysis was performed on all patients who underwent endovascular repair of the tho-
racic aorta with the Gore TAG device at our institution between March 23, 2005, and September 8, 2006.
Results: Fifty consecutive patients with a broad range of aortic pathologic conditions were included in the study.
The results in this group compared with those of the phase II trial included the following: length of stay, 7.5 versus
7.6 days (P ¼ .97); intensive care unit stay, 3.7 versus 2.6 days (P ¼ .61); 30-day mortality, 2.0% versus 1.5%
(P ¼ .68); spinal cord injury, 2% versus 3% (P ¼ .89); stroke, 4% versus 4% (P ¼ .67); early endoleaks, 26%
versus 4% (P< .01); and late endoleaks, 18% versus 7% (P ¼ .08). At 1 year, overall survival was 92% com-
pared with 82% in the phase II trial.
Conclusions: In the post-FDA approval era, endovascular stent-graft therapy is frequently applied to patients
with more challenging thoracic aortic anatomy and a wide range of pathologic conditions. Our results in this
group are similar to outcomes reported for patients with descending thoracic aortic aneurysm exclusively.In the early 1990s, treatment of thoracic aortic aneurysms
entered the endovascular era.1 Over the next decade, results
steadily improved as strict inclusion and exclusion criteria
were used to guide patient selection.2-5 Currently, one de-
vice, the Gore TAG thoracic endoprosthesis (W. L. Gore
& Associates, Flagstaff, Ariz) is approved by the Food and
Drug Administration (FDA) and commercially available in
the United States for the treatment of descending thoracic
aortic aneurysms. At least three other devices are in clinical
trials. With commercial availability, endovascular repair of
thoracic aortic disease has markedly increased. Off-label
use has rapidly expanded to include additional thoracic aor-
tic abnormalities such as pseudoaneurysm, type B aortic dis-
section, traumatic aortic disruption, complicated penetrating
ulcer, intramural hematoma, and lesions related to connec-
tive tissue disorders.6,7
The purpose of this study was to evaluate whether ‘‘post-
FDA approval era’’ outcomes are affected by the removal of
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PATIENTS AND METHODS
Study Design
After approval by the Institutional Review Board for Health Sciences Re-
search at the University of Virginia, a retrospective chart review of the first
50 consecutive patients who underwent thoracic aortic stent-graft therapy
with the Gore TAG thoracic endoprosthesis (W. L. Gore & Associates) after
FDA approval was performed. This included all patients who underwent
stent-graft placement from March 23, 2005, to September 8, 2006. Baseline
demographics, coexisting medical conditions, and specific indications for
endovascular repair were identified and recorded for each patient. Thoracic
aortic aneurysms were characterized as an emergency if frank rupture
or leak was imaged and urgent if the patient was symptomatic at the time
of presentation. Thoracic aortic dissections were categorized as acute if
repaired within 2 weeks of the initial onset of symptoms. Total length of
aortic exclusion after stent-graft therapy was calculated from postoperative
computed tomographic (CT) angiography using the centerline technique
and recorded. Length of stay, number of intensive care unit (ICU) days,
30-day mortality, complications, and overall survival were specifically an-
alyzed for each patient. The results of this analysis were then directly com-
pared with the results of the phase II multicenter trial of the Gore TAG
thoracic endoprosthesis2 to determine whether outcomes are significantly
altered once the well-controlled inclusion and exclusion criteria of clinical
trials are no longer strictly dictating patient selection.
Procedures
Patients were offered endovascular repair on the basis of suitability of
aortic anatomy, specifically, proximal and distal landing zones of at least
20 mm in length with diameters greater than 20 mm and less than
40 mm. Preoperative CT or magnetic resonance angiography was used to
delineate the anatomy, guide proper device size selection, and identifyardiovascular Surgery c Volume 137, Number 1 117




CSF ¼ cerebral spinal fluid
CT ¼ computed tomography
FDA ¼ Food and Drug Administration
ICU ¼ intensive care unit
indications for left subclavian artery revascularization before undergoing
thoracic endograft placement. Either left carotid–left subclavian arterial by-
pass or left subclavian transposition was performed for identification of an
incomplete posterior circulation, a left dominant vertebral artery, a patent
graft of the left internal thoracic artery to the left anterior descending coro-
nary artery, or an aberrant origin of the right subclavian artery.
Insertion of a lumbar catheter for cerebral spinal fluid (CSF) drainage
was performed preoperatively at the discretion of the surgeon after assess-
ment of risk factors for spinal ischemia including region of planned aortic
exclusion, length of planned aortic exclusion, and history of prior aortic pro-
cedure. Spinal drains were managed per protocol in the ICU setting and
were discontinued usually in 48 to 72 hours, before transfer to the surgical
department.
An endovascular team consisting of an interventional radiologist and ei-
ther a cardiac or vascular surgeon performed all operations. Procedures were
performed with the patient under general anesthesia with continuous arterial
pressure monitoring. Nearly all devices were introduced through the femo-
ral or iliac artery via direct arteriotomy, a polyester conduit, or percutane-
ously. Rarely, a graft was sewn directly to the infrarenal aorta to allow
for device delivery. Endografts were deployed by standard angiographic
and endovascular techniques. Intravascular ultrasound was used selectively.
All operations but two were performed in a negative pressure angiography
suite. The remaining procedures were carried out in the cardiac operating
theater. All patients recovered in the Thoracic and Cardiovascular ICU.
Patients underwent postoperative imaging, either CT or magnetic reso-
nance angiography, at 1, 6, and 12 months and yearly thereafter. Routine
clinical follow-up was conducted at the same interval. Patients with small
type I or II endoleaks at the conclusion of the procedure were imaged before
discharge to document resolution of the endoleak or the need for further in-
tervention. Patients with isolated type II endoleaks and no sac enlargement
were followed up routinely as described above.
Statistical Analysis
Results are presented as mean standard deviation, unless otherwise in-
dicated. Fisher’s exact test or c2 analysis was used to compare nominal data
to assess for differences between the two groups. P values were 2-tailed.
Overall survival and freedom from stent-graft–related event curves were
calculated by the Kaplan–Meier method.
RESULTS
Patient Characteristics
The first 50 consecutive patients to undergo thoracic aor-
tic stent-graft placement with the TAG endoprosthesis after
FDA approval were included in the study. Men slightly out-
numbered women, with 28 (56%) men and 22 (44%)
women undergoing the procedure. Ages ranged from 25 to
91 years with a mean of 64.8  14.9 years. Common med-
ical comorbidities are listed in Table 1, a patient population
similar to that of the phase II multicenter trial.2
Indications for endovascular repair are listed in Table 2.
Unlike the phase II multicenter trial, in which all patients
were treated for descending thoracic aortic aneurysm, our118 The Journal of Thoracic and Cardiovascular Supopulation included off-label indications such as ruptured
aneurysm, type B aortic dissection, acute traumatic disrup-
tion, penetrating ulcer with or without intramural hematoma,
thoracoabdominal aneurysm, aberrant right subclavian ar-
tery syndrome with dysphagia, exclusion of a left subclavian
artery aneurysm, and repair of a large type I endoleak after
stent-graft placement at an outside hospital. Thus, 19
(38%) of the initial 50 patients treated after approval of
the TAG device underwent stent-graft placement for a non-
approved indication.
Procedure Characteristics
Endovascular repair was successfully accomplished in all
50 patients. Procedure characteristics are detailed in Table 3.
Twenty-one (42%) patients required a conduit to either the
common or external iliac artery or infrarenal abdominal
aorta to bypass inadequate access vessels from the femoral
region. In all others, the endografts were delivered through
direct arteriotomy (42%) or percutaneously (16%) depend-
ing on the size and tortuosity of the femoral vessels and de-
gree of atherosclerotic disease present. Only 15% (P< .05)
of patients in the phase II trial had a conduit placed to facil-
itate introduction of the device.2
Zones of proximal aortic endograft attachment sites, as
defined by Criado and associates,8 are depicted in Figure 1.
Owing to inadequate length of the proximal landing zone,
the left subclavian artery was covered in 52% of the study
patients compared with 15% of patients in the phase II trial
(P<.05).2 Within our cohort, this included 20 patients with
exclusion of the left subclavian artery only, 2 patients with
exclusion of an aberrant right subclavian artery, 1 patient
with exclusion of an aberrant left vertebral artery, 1 patient
with planned exclusion of both the left subclavian and left
common carotid arteries, and 2 patients with exclusion of
all arch vessels with simultaneous arch reconstruction. In 1
patient with a type III thoracoabdominal aneurysm, the
TABLE 1. Patient characteristics
No. of patients (%)











Prior Aortic Surgery 14 (28)
Current Tobacco 19 (38)
CRI, Chronic renal insufficiency; COPD, chronic obstructive pulmonary disease;
CAD, coronary artery disease; CVA, cerebral vascular accident; PVD, peripheral
vascular disease.rgery c January 2009
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Dceliac trunk and superior mesenteric artery were excluded af-
ter a debranching procedure. Preemptive left carotid–left
subclavian bypass was performed in all 28 patients with ex-
clusion of the left subclavian artery during the phase II trial;
however, we used preemptive revascularization in only 6
(25%) patients excluding the 2 who underwent planned
arch vessel debranching procedures. Preemptive revascular-
ization was performed for aberrant origin of the right subcla-
vian artery in 2 patients, an incomplete posterior circulation
in 2 patients, anomalous aortic origin of a dominant left ver-
tebral artery in 1 patient, and stenosis of a codominant right
vertebral artery in 1 patient. The patient with planned cover-
age of the left common carotid and subclavian arteries un-
derwent a carotid–carotid bypass 1 day before stent-graft
placement with no left subclavian revascularization.
At the discretion of the individual surgeon, spinal drains
were placed preoperatively in 23 (46%) patients based on
factors that have been linked to increased rates of spinal is-
chemia: greater than 20 cm of total aortic exclusion, exclu-
sion of the distal descending thoracic aorta, and history of
prior aortic surgery. One patient had a spinal drain placed
postoperatively for paraplegia.
TABLE 2. Indications for thoracic aortic endovascular repair
Indications No. of patients (%)





Prior remote trauma 6 (60)
Prior remote surgery 4 (40)
Type B Dissections 6 (12)
Acute 5 (83)
Chronic 1 (17)
Acute Traumatic Aortic Disruption 3 (6)
Thoracoabdominal Aortic Aneurysms 2 (4)
Penetrating Ulcers 2 (4)
Aberrant Right Subclavian Artery Syndrome 1 (2)
Left Subclavian Artery Aneurysm 1 (2)
Type I Endoleak from Outside Hospital 1 (2)
TABLE 3. Procedure characteristics
No. of patients (%)
Aortic exclusion, mean (cm) 19.1  7.6
Left subclavian artery exclusion 26 (52)





Concomitant procedures 15 (30)
Estimated Blood Loss, mean (mL) 201  249The Journal of Thoracic andFor the purpose of the study, concomitant procedures
were defined as occurring during the same admission as
the stent-graft procedure, not necessarily the same anesthe-
sia event. Fifteen (30%) patients underwent concomitant
procedures, which ranged from endovascular procedures
such as stenting of the renal or iliac arteries or embolization
of the left subclavian artery to major surgical procedures
such as aorta–bifemoral bypass or arch reconstruction.
Outcomes
Postoperative outcomes of our first 50 consecutive pa-
tients who underwent thoracic stent-graft placement with
the TAG aortic endoprosthesis after FDA approval are com-
pared with those of the phase II multicenter trial in Table 4.
Specifically, there is no significant difference in number of
ICU days, length of stay, or 30-day mortality. On average,
study patients spent an extra day in the ICU compared
with patients in the phase II trial; however, with the exclu-
sion of the 3 patients who underwent stent-graft placement
for acute traumatic disruption, all of whom had severe poly-
trauma requiring prolonged ICU and hospital care, the mean
ICU stay decreased to 2.4 2.8 days and the mean length of
stay decreased to 5.3 4.7 days. Both values are lower than
those reported for the phase II trial. Within our patient group,
there was 1 death within the first 30 postoperative days. This
occurred in a 91-year-old woman who had a bradycardiac ar-
rest while ambulating 7 days after successful endovascular
FIGURE 1. Aortic arch map depicting sites of proximal endograft deploy-
ment.8Cardiovascular Surgery c Volume 137, Number 1 119
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Dexclusion of a leaking thoracic aortic aneurysm. At 1 year,
overall survival in study patients was 92% compared with
82% in the phase II trial (P ¼ .16).2
A comparison of early complications, defined as those oc-
curring in the first 30 days after the procedure, is detailed in
Table 5. With the exception of a higher endoleak rate in our
post-FDA approval group, no statistically significant differ-
ences were identified. The complications included small
type I endoleaks visualized on postdeployment aortography
while the patient was fully heparinized. Isolated type I endo-
leaks were identified in 7 patients. Four resolved spontane-
ously by 6 months, 1 persisted with no sac enlargement
and has been observed, 1 was associated with sac enlarge-
ment on CT angiography and was converted to open surgical
repair, and 1 was related to proximal endograft collapse that
was successfully treated endovascularly with placement of
a balloon expandable stent. Type II endoleaks were identi-
fied in 3 patients with no evidence of sac enlargement and
have therefore been observed. Finally, 2 patients demon-
strated both type I and II endoleaks. In both cases the type
I endoleak resolved spontaneously. One patient’s type II en-
doleak has been observed inasmuch as there has been no sac
enlargement, and 1 patient underwent successful transcath-
eter endoleak embolization with Onyx liquid embolic agent
(ev3, Irvine, Calif) when slight sac enlargement was de-
tected on CT angiography.
Spinal cord injury resulting in permanent paraplegia oc-
curred in 1 (2%) patient who had a ruptured thoracic aortic
aneurysm with persistent hypotension despite vasopressor
therapy preoperatively. Owing to the emergency nature of
TABLE 4. Outcomes: Post-FDA approval versus phase II trial2
Post-FDA,
n ¼ 50 (%)
Phase II trial,
n ¼ 139 (%)
P
value
Length of stay (d) 7.5  10.9 7.6  18 .97
ICU stay (d) 3.7  7.3 2.6  14.6 .61
30-Day mortality 1 (2) 2 (1.5) .68
FDA, Food and Drug Administration; ICU, intensive care unit.




n ¼ 50 (%)
Phase II trial,
n ¼ 139 (%)
P
value
Any major 17 (34) 45 (32) .93
Bleeding 5 (10) 12 (9) .94
Endoleak 12 (24) 5 (4) <.01
Vascular 5 (10) 20 (14) .63
Spinal cord injury 1 (2) 4 (3) .89
CVA/TIA 2 (4) 5 (4) .67
Pulmonary 2 (4) 14 (10) .31
Cardiac 4 (8) 4 (3) .28
Death 1 (2) 2 (1.5) .68
FDA, Food and Drug Administration; CVA, cerebrovascular accident; TIA, transient
ischemic attack.120 The Journal of Thoracic and Cardiovascular Surrepair, no spinal drain was placed preoperatively and the
patient’s aneurysm required greater than 20 cm of aortic ex-
clusion. Other neurologic complications included a cerebro-
vascular accident in 2 (4%) patients. In both cases the cause
was believed to be embolic. Both patients had significant
manipulation of their aortic arch with exclusion of at least
one arch vessel. Both patients’ symptoms resolved during
their admission.
Although not statistically significant, there were fewer
vascular complications in the post-FDA approval group
(8%) than in the phase II trial group (20%). Two vascular
complications related to access occurred, including one
failed percutaneous closure device, which required arterial
exposure and primary surgical closure, and an injury to the
right common iliac artery detected during removal of the de-
livery catheter, which was treated with an endovascular
stent. Additionally, 2 patients treated for dissection were
found to have persistent patency and retrograde filling of
the thoracic false lumen with aortic enlargement. In 1 pa-
tient’s case, the false lumen extended into the left renal
and left common iliac arteries. This was successfully treated
endovascularly with placement of stents bridging the true lu-
men of the aorta and the respective arteries with obliteration
of the false lumen within the branches.
Figure 2 demonstrates a Kaplan–Meier survival curve
showing freedom from overall and stent-graft–related mortal-
ity. With a mean follow-up of 625.1 days, overall survival
was 88% and freedom from stent-graft–related death was
100%. Of the 6 nonsurvivors, 3 died of cancer-related causes,
2 of cardiac-related causes, and 1 patient of pneumonia.
Table 6 compares late complications, those occurring
greater than 30 days after the procedure, between the two
groups and demonstrates no statistically significant
FIGURE 2. Kaplan–Meier curves of stent-graft–related and overall sur-
vival.gery c January 2009
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further intervention at 1 year. In the post-FDA group, only
one new endoleak developed during the follow-up interval.
This was either a type II or III endoleak with no change in
aortic diameter and has therefore only been observed.
DISCUSSION
The history of endovascular repair of descending thoracic
aneurysms has been well documented since first reported in
a high-risk population by Dake and associates1 in 1994. Al-
though complication rates were relatively high with this first
generation of devices, the development of multiple commer-
cially manufactured endografts with improved flexibility
and durability markedly decreased the number of complica-
tions.2-5 Many groups have since reported superior short-
term and midterm results to those of conventional open
surgery, including decreased operative time, shorter ICU
and hospital stays, and lower perioperative morbidity and
mortality rates.9,10
In March of 2005, after an advisory panel review of the
results of the phase II multicenter trial with the TAG endo-
prosthesis,2 the FDA approved the device to become the first
commercially available endograft in the United States to
treat descending thoracic aneurysms. After this decision,
clearly mandated training instructions for use accompanied
the commercialization process; however, the well-controlled
inclusion and exclusion criteria that governed patient selec-
tion in the clinical trials could no longer be strictly enforced.
Off-label indications have rapidly expanded to include addi-
tional thoracic aortic diseases such as ruptured aneurysm,
type B aortic dissection, traumatic aortic disruption, compli-
cated penetrating ulcer, intramural hematoma, and treatment
of lesions related to connective tissue disorders. The current
report describes our single-center, ‘‘real world’’ experience
with this device since it received FDA approval and favor-
ably compares our results with those of the phase II multi-
center trial.
Similar comparisons have been made in the literature re-
garding endovascular repair of abdominal aortic aneurysms,
including two separate studies that have compared their
post-FDA approval single-center experiences with that of
the overall multicenter trials data.11,12 Both studies reported
TABLE 6. Late complications (1-year follow-up): Post-FDA approval
versus phase II trial2,16
Late events
Post-FDA,





Migration, proximal 0 0/97 (0) .999
Migration, distal 0 1/84 (1) .67
Endoleak rate 8 (16) 7/97 (7) .15
Conversion to open 1 (2) 1/109 (1) .81
Endovascular revision 3 (6) 1/109 (1) .19
1-Year overall survival 46 (92) 89 (82) .16
FDA, Food and Drug Administration.The Journal of Thoracic and Cno significant differences in complication and mortality rates
between the trial groups and the post-FDA approval groups;
however, they concluded that extending endovascular indi-
cations to treat increasingly complex aortic aneurysms, in-
cluding those with short, angulated necks, had resulted in
increased numbers of type I endoleaks. Further, Adelman
and colleagues12 demonstrated that significantly more pa-
tients in the post-FDA approval group required additional
access procedures such as iliac angioplasty or stenting, con-
duits, or either iliofemoral or femorofemoral bypass to intro-
duce the device. Although we report similar findings in our
own post-FDA experience with the TAG device, endovascu-
lar treatment of the thoracic aorta differs from its abdominal
counterpart in that thoracic endovascular therapy may be
applied to multiple aortic diseases, not just aneurysms.
Although the phase II trial investigated thoracic aortic
stent grafts for the treatment of descending thoracic aneu-
rysms only, the indications for treatment in the post-FDA
approval study group included multiple aortic diseases.
The distribution of individual aortic pathologic conditions is
similar to that of Verhoye and coworkers,6 who reported
a nearly 5-year experience with thoracic stent grafting at
two centers in France. The authors sought to evaluate out-
comes based on acute versus chronic disease entities. In com-
parison with our study, similar perioperative morbidity and
mortality were reported using three different stent-graft sys-
tems (Talent, Medtronic, Inc, Santa Rosa, Calif; TX2,
Cook, Inc, Bloomington, Ind; and the TAG, W. L. Gore &
Associates, Inc, Flagstaff, Ariz). A higher endoleak rate
(29.6% vs 16%; P¼ .16) was reported in their study, the ma-
jority occurring in the chronic pathology group. They con-
cluded that in their hands, thoracic aortic stent-graft therapy
was particularly effective in the treatment of acute diseases
such as complicated acute type B dissections, acute traumatic
rupture, and symptomatic penetrating ulcers, as well as
chronic pseudoaneurysms from prior surgery or trauma.
Less common indications for endograft placement in the
thoracic aorta may include purposeful exclusion of vascular
abnormalities involving various aortic branches. In our se-
ries, an endograft was successfully used to exclude a retroe-
sophageal aberrant right subclavian artery causing severe
dysphagia, as well as a proximal left subclavian artery aneu-
rysm in another patient.
When comparing our early adverse events to those of
the phase II trial, we observed a significantly higher endo-
leak rate (24% vs 4%; P < .01). During intraoperative
aortography or in the early postoperative period, we noted
more proximal type I endoleaks (8) than reported in the
phase II trial (1), with nearly equal type II endoleaks. It
is likely that this difference is due to our willingness to
challenge more hostile aortic arches not permitted by ana-
tomic constraints dictated by clinical trial protocols. This is
supported by the fact that 6% of patients had the proximal
endograft attachment site in zones 0 and 1 (which was notardiovascular Surgery c Volume 137, Number 1 121
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required to exclude the left subclavian artery (52% vs
15% in the phase II trial; P< .0001) to obtain a dimen-
sionally suitable proximal landing zone. As previously dis-
cussed, this tends to place the proximal aspect of the
endograft into the horizontal segment of the aortic arch,
thereby increasing the chances for poor opposition of the
endograft along the inner curve of the aortic arch apex,
which may promote creation of a perigraft endoleak chan-
nel. Ideas for future devices to combat this problem may
include flared endografts or smaller articulations that
would allow the endograft to conform better to the natural
arch angle.
An additional topic related to coverage of the left subcla-
vian artery that warrants further discussion is our approach
to revascularization after exclusion. As previously reported,
we used a policy of selective revascularization in contrast to
the phase II trial, in which a bypass was performed univer-
sally in conjunction with planned exclusion of the left sub-
clavian artery. Excluding planned debranching procedures,
this series included adjunctive left subclavian artery bypass
or transposition in 6 (25%) patients. After intentional left
subclavian occlusion without associated surgical revascular-
ization, 3 patients had left arm effort discomfort. Late revas-
cularization was required in 2 of the 3 additional patients
(11%). One patient’s symptoms resolved after cardiac reha-
bilitation. Interestingly, the 2 patients requiring bypass were
both women, under 40 years of age, and treated for a pseu-
doaneurysm.
Neurologic complications continue to be a rare but devas-
tating complication of thoracic aortic stent grafting. Spinal
cord ischemia, both immediate and delayed, resulting in
paraplegia has been reported in multiple series. In these,
its occurrence most commonly ranges from 3% to 5%
and appears to be a multifactorial event.13 As previously
stated, our single episode of spinal cord injury developed
in the immediate postoperative period after emergency re-
pair of a ruptured thoracic aortic aneurysm and did not re-
spond to delayed CSF drainage, steroid administration,
and aggressive blood pressure control. Multiple risk factors
have been implicated, including an aortic treatment length
greater than 20 cm, coverage of the distal thoracic aorta be-
tween the T8 and L2 vertebral levels, and a history of prior
abdominal aortic repair.14 Perioperative hypotension, de-
fined as a mean arterial pressure less than 70 mm Hg, has
also been implicated as a risk factor for both immediate
and delayed spinal cord injury.15 Like many authors, we ad-
vocate the use of prophylactic CSF drainage in patients with
these preoperative risk factors and closely manage blood
pressure in the perioperative period to maintain a mean arte-
rial pressure greater than 90 mm Hg.
Strokes have also been reported after thoracic stent-graft
procedures, especially in patients requiring extensive aortic
arch manipulation.2 Identical to the frequency detailed for122 The Journal of Thoracic and Cardiovascular Suthe phase II trial, we report a 4% rate of stroke. Within
both groups, strokes occurred almost exclusively in patients
requiring coverage of the left subclavian artery. This is likely
not the only factor inasmuch as the stroke rates were identi-
cal despite the notable increased frequency of arch vessel
coverage in our group (52%) compared with that in the
phase II report (15%). Risks of embolic cerebrovascular
events are likely related to the severity and composition of
the aortic atherosclerotic plaques and the extent of wire,
catheter, and device manipulation within the arch.
Finally, vascular access to the thoracic aorta continues to
be a significant issue with thoracic aortic endografting. Vas-
cular complications related to access were more frequently
reported in the phase II trial than in our post-FDA approval
group (14% vs 10%; P ¼ .63), although this did not reach
statistical significance. Contributing to this, as the phase II
authors pointed out, is an appreciation of the critical value
of using a graft conduit as a preemptive measure rather
than a bailout after a vascular injury has occurred.2 In our
post-FDA approval group, a conduit for arterial access was
used in 42% of patients (5 men, 16 women), emphasizing
the more frequent need in women secondary to smaller iliac
and femoral vessels.
CONCLUSION
The outcomes of this study demonstrate that in the post-
FDA approval era of the TAG endoprosthesis, we are
achieving similar results to those of the phase II multicenter
trial as we apply endovascular repair to a wider range of tho-
racic aortic diseases and more difficult aortic and iliac anat-
omy. Although this study has limitations, including those of
being a nonrandomized, retrospective review that is subject
to inherent bias, we believe the data further contribute to the
ever-growing body of evidence supporting the use of tho-
racic stent grafts for a variety of thoracic aortic lesions.
We thank Diane Washington for her assistance in preparing this
manuscript and Donald L. Persson for providing the illustration
presented in Figure 1.
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